AKBA - Akebia Therapeutics Stock Trading

This article is part of a series that provide an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarman’s regulatory 13F Form filed on 02/13/2020. Please visit our Tracking Seth Klarman’s Baupost Group Holdings ...

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today announced that its President and Chief Executive Officer, John P. Butler, will present at the 38 th Annual J.P...

Historian -- an unsuccessful novelist ." - H.L. Mencken Today, we take a deeper look at a small biotech concern that has been very volatile in its history as a public company. However, it has potential catalysts on the horizon and has picked up some insider buying of late as well. A full...